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ABSTRACT  Interferon  is one  determinant of host resistance. The immune re-
sponses,  cellular  or  humoral,  are  other  components.  Cell-mediated  responses
appear to be involved in host resistance to certain viral infections, particularly
the herpesvirus  group  and vaccinia  virus.  It  is  suggested  that immune  and in-
terferon  responses  may  complement  one  another  and  contribute  to host  re-
sistance.  The relative  importance  of each component  depends  upon the virus-
host  interaction.  Finally,  evidence  has  been  presented  which  suggests  that
production  of interferon  as  a  result of antigen-sensitized  cell  interaction  may
further link these two components  of the host response.
Host  resistance  to viral  infections  is  a  complex  phenomenon.  Following  the
discovery  of interferon by Isaacs  and Lindenmann  in  1957  (1),  a significant
body of evidence  has  developed  which  suggests that  this antiviral substance
is an important  determinant  of host resistance  (2).  In  another paper  in  this
Symposium,  Dr. Baron  (3)  has reviewed  the contribution of interferon  to the
host's defense mechanisms.
The  purpose  of this  report  is  to  consider  the function  of interferon  as it
interrelates with both the humoral and cellular immune responses  of the host
during the course of viral infections.
VIRAL  PATHOGENESIS
As background for our discussion, a schematic illustration of viral pathogenesis
is  presented  in  Fig.  1. Infection  is usually initiated  at a  local  site,  e.g.,  the
respiratory  tract.  Virus  replication  may  occur  at  this  site  resulting  in  the
production  of disease.  Alternatively,  if the  particular  agent  has the capacity
to invade the  host and produce  systemic  disease,  virus may spread from  the
local  site  of infection  through  the  blood  to  target  organs;  occasionally  this
spread may occur through lymphatics or nerves. During this primary viremic
phase virus particles are exposed  to leukocytes or phagocytic cells of the reticu-
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FIGURE  1.  A  schematic  diagram  representing  the  pathogenesis  of many  acute  viral
infections.
loendothelial  system and may or may not be cleared from the circulation  by
these cells,  depending  upon the virus and  the  host. If  a virus  is taken  up by
leukocytes  or phagocytic cells, the  outcome of this virus-cell interaction  may
be  a  critical  determinant  of the subsequent  course  of the infection.  Having
achieved  an intracellular  position, the agents  may (a)  fail to replicate and be
controlled  by the  host,  (b)  multiply  and produce  disease,  (c)  multiply  and
through a secondary viremia reach target organs,  or (d) be carried to distant
sites of infection  within the circulating leukocytes.
Mims  (4)  has reviewed the significant body of evidence which suggests that
the interaction  of virus with phagocytic  cells of the reticuloendothelial  system
may be a critical determinant in blocking further spread of the virus to poten-
tial  target organs.  Work from  our own laboratory  (5)  has  indicated that in
an in vitro model, mouse macrophages have the capacity to control the spread
of vaccinia virus within an otherwise susceptible population of cells.  In  certain
viral infections this interaction may be the common denominator in the initia-
tion of both the interferon and the immune response.  Present immunological
concepts  indicate  that  processing  ofan  antigen  by macrophages  is  the first
step  in initiation  of the production of humoral antibody.  Similarly,  evidence
has been  presented  which suggests  that phagocytic  cells of the reticuloendo-
thelial system also may serve as the source for interferon present in the serum
early during the course of a viremia. Thus in certain viral infections  both the
immune and interferon responses may have a common cell pathway in at least
one phase of the host response.
HOST  RESISTANCE
A  wide  variety  of physiological  factors  have  been  implicated  in  the host's
defenses  against  a virus  infection.  In  Fig.  2  this  complexity  is  schematically
illustrated in terms of the children's fable about the six blind men attempting
to define the nature of an elephant.  The intent of this illustration  is to point
out (a) the difficulty in our attempts to define the nature of the host response
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FIGURE  2.  See  text for explanation.
in  situations  where  we  frequently  are  limited  in  our ability  to  define more
than one or two parameters,  and  (b)  the  importance of directing  our efforts
toward  examination  and  delineation  of  a  more  complete  picture  of  host
resistance.
INTERFERON  AND  THE  IMMUNE  RESPONSE
In  discussions  of host resistance  frequently  we have  let ourselves  be trapped
into considering interferon  "vs."  antibody. This  is unfortunate because  it has
created  an "either-or"  atmosphere.  Rather,  it would seem  more reasonable
to approach  the problem  from the  point of view  of  trying to  integrate  the
various  factors contributing  to  host resistance.  This leads  us to consider  the
following question.  How do  both interferon  and  antibody contribute  to host
resistance? As the first step in answering this query, the nature of the antiviral
action  of interferon  and  humoral antibody  are  compared  in Table  I.
If  one seeks logic in biological phenomenon  these two host defenses  appear
to be logically complementary.  Interferon may be rapidly produced and may
establish  its antiviral  activity before the infection  is  established  in the target
organ  and  prior  to  the  presence  of  neutralizing  antibody.  Interferon  acts
intracellularly  while antibody is not able to act on a virus in an intracellular
location.  Finally,  interferon  may be produced and  act at the local  site of in-
fection in contrast with the usual production of antibody at a distant site.  In
each  of these  characteristics  interferon  appears to complement  the action  of
neutralizing  antibody.  The  contribution  of  each  of these  factors  obviously
will not be resolved until either  interferon  or antibody can be selectively  in-
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TABLE  I
CHARACTERISTICS  OF  INTERFERON  AND  ANTIBODY
Interferon  Antibody
Produced  by  all cells  Produced  by specific  cells
Produced at site  of infection  Produced  at distant site
Action-intracellular  Action-extracellular
Production time--hours  Production time-hours-days
Virus  nonspecific  (broad spectrum)  Virus specific
hibited  in experimental  model  infections.  In the meantime the working  hy-
pothesis that  appears most  attractive  is  to  consider these components  of the
host  response  supplementary  rather  than  competitive.  Depending  on  the
virus-host  relationship  one or  the  other  may  be  of greater  importance,  or
even both factors  together may be of lesser significance  while other determi-
nants assume  a more critical role.
HOST  RESISTANCE  TO  ENCEPHALOMYOCARDITIS
VIRUS  INFECTION
We have carried  out a series of investigations concerning  the relative  role  of
interferon  and  antibody  in  host  resistance  in  one  model  of a systemic viral
infection, encephalomyocarditis  virus (EMC) in mice  (6-9).  The pathogene-
sis  of EMC  virus  is schematically  illustrated  in Fig.  3.  After  intraperitoneal
inoculation, primary replication occurs in lymphatic tissue with seeding of the
blood followed by infection of target organs including the heart and the brain.
Two aspects  of the host  response,  e.g.  production  of interferon  and  specific
neutralizing  antibody,  are  illustrated  in  this  figure.  We  have  consistently
found that clearance  of viremia has  been  associated  with the appearance  of
neutralizing  antibody. This has been  observed to occur as early as 72 hr after
infection.  We  have interpreted  these  data to  indicate that  clearance  of the
viremia  is  directly  related  to  the  production  of  specific  antibody  and that
initial formation of antibody begins earlier than the time we are first able to
detect it (72-120 hr).
Mice  receiving  whole  body X-irradiation  or  immunosuppressive  therapy
with cyclophosphamide  (cytoxan)  and  thioquanine  manifested  an  increased
susceptibility  to EMC  virus  (7).  The  mortality of mice infected  with EMC
virus was increased from 0 in control animals to 90%  in mice receiving cytoxan
and  thioquanine. Animals  receiving  immunosuppressive  therapy  were found
to have  a delay in  appearance  of neutralizing  antibody associated  with per-
sistence  of the  viremia  and enhanced  multiplication  of virus  in  the target
organs. The levels of virus present during the viremia in control and immuno-
suppressed  animals  as  well  as the timing  and  magnitude  of the immune  re-
sponse in experimental and control groups of mice are summarized  in Fig. 4.
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FIGuRE  3.  A diagram  of the quantity of virus in the blood,  heart, and brain (p.f.u./g)
during infection of mice with encephalomyocarditis  (EMC) virus, and the levels of inter-
feron and  antibody in the serum, produced in response to infection.
Interferon  levels were similar  in  control  and immunosuppressed  animals  in
spite  of the  fact  that  significantly  greater  levels  of virus  were  found  in  the
blood of the experimental  group. These data are summarized in Fig.  5.  Simi-
lar results have been  obtained with animals receiving whole body X-irradia-
tion  ().  Since  neutralizing  antibody  could  never  be  detected  during  the
course of an experiment  in mice receiving X-irradiation,  the effect of admin-
istration  of hyperimmune  anti-EMC  antibody  on  the  course  of  infection  is
illustrated in Fig.  6.  The mortality  rate was increased  from  10%  to approxi-
mately 90%  in X-irradiated  animals.  Only one  animal died from X-irradia-
tion alone.  Hyperimmune  serum was administered  24 hr prior to,  simultane-
ously  with,  or  at  daily  intervals  from  day  1 through  6 following  infection.
The purpose of this experiment was to determine whether the earlier presence
of neutralizing antibody,  presumably by shortening the viremic phase, would
decrease seeding of target organs and protect the animal.  Susceptibility of the
X-irradiated  mice could be reversed  by passive transfer of neutralizing anti-
body  as  late  as  72  hr  after infection.  This timing  correlated  with the usual
time of clearance  of the viremic phase in normal control animals. These data
have been  interpreted  to indicate that the decreased  capacity of immunosup-
pressed and X-irradiated  animals to produce antibody was a critical determi-
nant of host resistance and that the delayed  appearance  of antibody  resulted
in an enhanced viremic phase with increased seeding of target organs, greater
multiplication,  and death of the animal.  In this experimental  model we have
viewed  the function  of  antibody,  as schematically  illustrated  in  Fig.  7,  as  a
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FIGURE  4.  Levels  of virus  and neutralizing  antibody  in  blood  of mice  infected  with
EMC  virus.  Titers in  animals  receiving  cyclophosphamide  (cytoxan)  and  thioguanine
are compared with nontreated, control animals. Figure  reprinted  by permission  from the Ameri-
can Society for Microbiology (7).
factor limiting the spread of virus to target organs.  In interpretation  of these
data it should be recognized  that any specific conclusions are clearly limited
by the wide range of nonspecific  effects  that X-irradiation  and immunosup-
pressive therapy  may have on the host.
To further test this hypothesis  a formalized  EMC  virus  vaccine  was pre-
pared.  This vaccine  was shown to  contain  no infectious  virus particles,  and
there  was  no  evidence  of  replication  of virus  either  in  tissue culture  or  in
X-irradiated  animals.  Furthermore,  the vaccine preparation  did not  induce
interferon either in tissue culture or in vivo. The administration  of the vaccine
induced  the production  of specific  neutralizing  antibody within  72 hr of an
intraperitoneal  inoculation.  In another  study carried  out with Dr. Friedman,
we demonstrated  that male mice are  significantly  more  susceptible  to EMC
virus than  are  females.  If our interpretation  of the role of antibody  in host
resistance  to EMC virus is valid then the inoculation  of the vaccine prior to
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FIGURE  5.  Levels of interferon  in serum  of mice receiving cyclophosphamide  (cytoxan)
and, thioguanine,  compared  with  control  animals,  after  infection  with  EMC  virus.
Figure  reprinted by permission  from the American Society for Microbiology (7).
virus infection  might be expected to induce  the earlier formation of antibody
in recipient  mice.  If  the immune  response  were initiated more rapidly, then
the viremic  phase should  be  shortened,  seeding  to  target  organs  decreased,
and animals protected against infection. The data presented in Fig.  8 demon-
strate  that the  administration  of vaccine  36 hr prior  to infection  with EMC
virus does,  in  fact,  result  in  a  significant  degree  of protection  in  the  more
susceptible  male  animals.  We've  interpreted  these data  to support  the con-
cept  that  neutralizing  antibody  affects  the  duration  of  the viremic  phase,
secondarily  the degree  of seeding  of target organs and ultimately  survival  of
the animal.
In  considering  EMC  as  a  model  infection  we  have  recognized  that  the
EMC-host  relationship  must  be considered  individually,  and  it is  in  these
terms  that we have  developed  our concept of host resistance.  The individual
variation in the interferon response may be illustrated by comparing the New-
castle  disease  virus  (NDV)-host  interaction  with that  of EMC  virus.  NDV
induces  10,000-50,000  U/ml in  the  serum of mice  2-6 hr  after inoculation,
i218  s
. AftL.  GLASGOW  Interrelationships  of Interferon and Immunity
K
-4
KZ
%  -- y----J  _-I 0  +1  +2  +3  +4  +5  +6
CONTROL  DAY OF ADMINISTRATION  OF HYPERIMMUNE
NONIMMUNE  SERUM  ANTI-EMC  SERUM
FIGURE  6.  The  effect  of time  of administration  of anti-EMC  immune  serum  on the
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FIGURE  7.  A schematic illustration of the role of antibody in decreasing the viremia, thus
reducing the size of the inoculum reaching target organs during the viremic phase.
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FIGURE 8.  The mortality  rate in male  and female  mice  infected  with  encephalomyo-
carditis  (EMC) virus  36 hr  after receiving a formalized  EMC virus vaccine or a control
inoculation  (adjuvant or balanced  salt solution).
while EMC virus stimulates only 50-150 U with peak levels not being reached
until 24-48 hr after inoculation. It  seems highly unlikely that interferon could
make the  same contribution  to  host resistance  in these  two virus-host  rela-
tionships.
CELLULAR  IMMUNITY
Dr. Baron  (3)  has focused principally upon the host response during primary
infection; I would now like to direct our attention to an area in which inter-
feron  and  immune responses  of the  host may  be  more  directly  related.  As
background  we should briefly consider the cellular  aspect of the immune re-
sponse.  Cooper and  coworkers  (10)  have  presented the  concept  of the  two-
component immune system. One population of cells derived from the thymus
is  related to cellular  immunity; the  other derived from the  bursa in chickens
or Peyer's patches lymphoid tissue in mammals is responsible for the humoral
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antibody response.  In recent years a number of clinical conditions have been
recognized  which are  associated  with enhanced  susceptibility  to  viral  infec-
tions (11-17).  A common denominator  of many  of these situations  has been
impairment  of the  immune  response.  In  accord  with  the  two-component
concept of the immune response, clinical conditions associated with enhanced
susceptibility  in Table  II have  been divided  into the following  three general
TABLE  II
CLINICAL CONDITIONS CHARACTERIZED BY IMMUNOLOGICAL
DEFICIENCY  AND  INCREASED  SUSCEPTIBILITY
TO VIRAL  INFECTION
Malignancy and/or Immunosuppression
1.  Varicella
2.  Vaccinia
3.  Cytomegalovirus
4. Measles
5.  Herpes
Immunological Deficiency Diseases
A.  Decreased  immunoglobulin  production  with normal  thymic  function
1.  Poliovirus, vaccine  strain
2.  ECHO
3.  Serum hepatitis
4.  Cytomegalovirus
5.  Adenovirus
6. Varicella
7.  Vaccinia
B.  Normal immunoglobulin  production with  thymic deficiency
1.  Vaccinia
2.  Measles
C.  Decreased  immunoglobulin  production with  thymic dysfunction
1.  Vaccinia
2.  Measles
3.  Varicella
4.  Cytomegalovirus
5.  Adenovirus
D.  Wiskott-Aldrich  Syndrome
1.  Herpes  simplex
2.  Cytomegalovirus
3.  Measles
groups:  (a) decreased  immunoglobulin production with normal thymus func-
tion,  (b) normal immunoglobulin production  with impaired thymus function,
and (c) varying degrees  of combined dysfunction  of both components  of the
immune  mechanism.  Although  there  are  some  exceptions,  the  majority  of
individuals  in the group with deficiency  of humoral antibody  formation but
intact thymus function develop normal delayed hypersensitivity reactions and
handle most viral infections  in a relatively  normal  fashion.  This supports the
general concept  presented  by Dr.  Baron  (2,  3)  of the relatively  limited role
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of neutralizing antibody in many primary viral infections.  In contrast children
with various conditions involving  dysfunction or aplasia of the thymus mani-
fest a pattern  of deficiency  of cellular  immunity  as evidenced  by a  reduced
capacity  to reject homografts and failure to develop delayed  hypersensitivity.
It is  this  group  of individuals  who  are  most conspicuous  in  their  impaired
capacity  to control  a number of viral infections.
The following two general patterns emerge from these experiences:  (a) from
the point of view of the host--conditions  in which cell immunity is impaired
alone  or in combination  with other components  of the  host response  are  as-
sociated  with  increased  susceptibility  of the  host to  certain  viral  infections,
particularly herpesvirus, vaccinia virus, cytomegalovirus,  and perhaps measles
virus; (b)  from the virus aspect-cytomegalovirus,  herpesvirus,  vaccinia virus,
are all agents in which cell-to-cell  transmission  of virus is characteristic  of the
pathogenesis  of the  virus.  Although  current  knowledge  does  not  permit  an
explanation  of these patterns they strongly  suggest a causal relationship.
IMMUNOSUPPRESSION-EXPERIMENTAL  MODELS
The effect  of immunosuppressive  therapy  on experimental  infections in  ani-
mals  has been  widely investigated  and  tends to  support the general  concept
which has been presented. This interpretation,  as we have indicated,  must be
limited  by the knowledge  that most methods  used  to produce  immunosup-
pression have multiple sites of action and may adversely  affect more than one
component of host resistance.
Within  these  limitations,  one  interesting  study  by Fulginitil supports  the
theme of this discussion, namely  the interrelationship between  interferon  and
the immune  response.  In  this  study X-irradiation  and  antilymphocyte  sera
were utilized as suppressants of host resistance  in monkeys  infected with vac-
cinia virus.  In animals treated  with antilymphocyte  sera,  the vaccinia  virus
lesions  were  larger  and  contained  more  virus.  Furthermore  virus  was  dis-
seminated  with development  of secondary  lesions  over the entire  body.  De-
layed  hypersensitivity  skin tests  to vaccinia  virus  antigen  were  markedly  re-
duced  in  size,  but  serum  antibody  and  interferon  levels  were  comparable
with control animals. Discontinuation of the administration of antilymphocyte
sera was followed by a cellular response  at the site of infection,  development
of a  delayed  hypersensitivity  reaction  at  the  vaccination  site,  and  eventual
clearing  of all  lesions.  In  primates  receiving  a  lethal dose  of X-irradiation,
vaccinia  virus  rapidly  became  disseminated  from  the  necrotic,  nonhealing
primary vaccination  site. In two animals the infection with vaccinia  virus was
controlled.  Both  animals  had  restoration  of lymphatic  tissue.  One  of  these
occurred  spontaneously,  the other was  produced  experimentally by replace-
1 Fulginiti, V. A.  Simian vaccinia  virus infection.  Presented at Society for Pediatric Research Meet-
ing,  Atlantic  City, New Jersey,  in May,  1969. Manuscript  in preparation.
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ment of bone marrow.  Lymphatic  restoration  was associated  with reappear-
ance  of lymphocytes,  development  of delayed  hypersensitivity,  and recovery
of the  capacity  to  synthesize  interferon  at  the local  site  of virus  infection.
These data have been interpreted  to indicate that the presence  of cellular im-
munity  or of at least cell-mediated  responses  appears  to correlate  with  host
resistance.  The combined  loss of capacity to produce  interferon and humoral
antibody in the X-irradiated animals was associated with a greater enhance-
ment of susceptibility  than occurred  with the administration  of antilympho-
cyte sera alone. Recovery of cellular response and the capability of interferon
production also were associated with restoration of the host's capacity to con-
trol vaccinia virus infection.  These  results support the concept that lympho-
cytes  and cell-mediated  responses may be critical determinants  of host resist-
ance  to  vaccinia  virus  infections.  The  data  also  strongly  suggest  that  host
resistance  is  a  multifactorial  phenomenon  and  that each  component,  inter-
feron and the cellular and humoral immune response,  contributes to the host
defense against infection with vaccinia virus. Although certainly not definitive,
this  study  suggests  the  possible  interrelationship  between  cellular  immune
response and  interferon.
The clinical observations which were reviewed,  as well  as the experimental
evidence  of which Fulginiti's  study  is one example,  suggest  that cellular  im-
munity contributes  to host resistance.  It is important to  bear in mind,  how-
ever, that results of immunosuppression  on experimental  virus infection have
included the following:  (a)  enhanced  susceptibility of the host,  (b)  enhanced
resistance of the host,  and  (c) no recognizable  effect.  Under these conditions,
it is evident that the role of the various components  of host response depends
upon the nature of the virus-host interaction,  and that the immune response
may, in certain virus infections,  contribute to the virulence  or pathogenesis  of
the virus while in others  a cellular  component  of the immune response  may
also  be a contributor  to host resistance.
INTERRELATIONSHIP  OF  INTERFERON  AND  CELLU-
LAR  IMMUNITY
The complexity of altered responses or reactions  of the immune cell  on expo-
sure to specific  antigen has  been  increasingly  recognized.  Fig. 9 summarizes
the wide  spectrum  of cell  responses which  may result  from  this interaction.
For the purpose  of this  discussion  attention  will be focused  on  the evidence
which suggests that induction of interferon production may be one of the  al-
tered  responses  of the  immune cell  and  may  provide  another  link  between
these two components of the host's defense mechanism.  Several years  ago we
reported  (18)  the observation that peritoneal macrophages from mice immu-
nized to Chikungunya  virus  (CV) produced increased levels  of interferon  on
reexposure  to  the  same agent  in vitro.  This reaction  is  specific  for  CV and
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IMMUNE  CELL  (Lymphocyte  or Macrophage)
± Antigen
4_
-Transfer  Factor
- Lymphotoxin
- Migration  Inhibitory Factor
_  Chemotactic Factor
- Blastic Transformation
- Enhanced RNA  Synthesis
- Enhanced DNA  Synthesis
- Interferon
- Cytolytic Reaction
- Immunological  Memory
- Antibody Synthesis
- Enhanced  Phagocytosis
- Increased Hydrolytic Enzymes
- Increased  Bacteriocidal Activity
- Enhanced  Protein Synthesis
FIGURE 9.  A summary of the products and altered reactions or responses of (a)  immune
cells or  (b)  immune cells following  interaction with  antigen.
could  not be correlated with  (a)  enhanced  uptake of virus by immune cells,
(b)  the  presence  of cytophilic  antibody,  or  (c)  the  presence  of neutralizing
antibody.  It  was postulated that the immune cell  might have an altered ca-
pacity to  respond  on reexposure to a virus and that enhanced interferon pro-
duction was one  manifestation  of this altered  reactivity.  If this phenomenon
also  occurs in the intact animal  it will further  suggest a possible mechanism
for cellular  immunity  to viral  infection  in vivo  and will  establish a relation-
ship between interferon  and the immune response.
More  recently  work  from  a  number  of  laboratories  has  confirmed  and
extended  this  concept.  Similar  results  have  been  obtained by  Yamada  and
Azuma  (19) who observed that interferon  production was markedly increased
in macrophages harvested from the peritoneal cavity of mice immunized with
NDV or Sindbis virus and exposed to the corresponding agent in tissue culture.
The potential significance  of these observations has been broadened by the
recent  studies  of Green,  Cooperband,  and  Kibrick  (20)  who  extended  the
phenomenon  from that of a virus-immune  cell interaction  to a more general
interaction  of antigen  with  immune  cells.  They  demonstrated  that human
leukocytes  from  individuals  with  sensitivity  to  tuberculin,  tetanus,  or
diphtheria toxin  produced  interferon  on  exposure  to the  respective  antigens
in vitro.  Reaction  was specific  for cells  from immune  donors and could  not
be found in nonsensitized cells.  Evidence that this phenomenon  occurs in the
intact  animal  as  well  as  in  tissue  culture  has been  demonstrated  by  Stine-
bring  and Absher  (21).  They found that mice which had been  sensitized  to
Mycobacterium  tuberculosis produced  strikingly  greater  levels  of  interferon  in
the serum  following inoculation  of PPD  than control,  nonsensitized  animals.
This series  of investigations supports  the concept  that interferon  production
may  represent  one  manifestation  of  the  altered  reactivity  of  the  immune
leukocyte or macrophage on reexposure to the immunizing antigen. The data
further  suggest that production  of interferon  by the immune cell exposed  to
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specific  antigen may have implications  for the intact animal as well  as tissue
culture models.  The  question  of the potential function  in  the intact animal
remains intriguing but unanswered.
SUMMARY
Interferon  is one determinant of host resistance. The immune responses, cellu-
lar or humoral,  are other components.  Cell-mediated  responses appear to be
involved  in host resistance  to certain viral infections,  particularly  the herpes-
virus  group  and vaccinia  virus.  It is  suggested  that immune  and interferon
responses may compliment one another and contribute to host resistance. The
relative  importance  of each component depends  upon the virus-host interac-
tion.  Finally,  evidence  has  been  presented  which  suggests  that  production
of interferon  as a result of antigen-sensitized  cell interaction  may further link
these two components of the host response.
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